ProQR Therapeutics (PRQR) Equity Income (2019 - 2022)

ProQR Therapeutics (PRQR) posted Equity Income of -$8978.7 for Q1 2022, up 90.77% sequentially from -$97237.5 in Q4 2021.

ProQR Therapeutics (PRQR) Equity Income (2019 - 2022) Analysis & Trends

ProQR Therapeutics has reported Equity Income for 4 years, with the latest figure at -$8978.7 in Q1 2022.

Quarterly Equity Income changed N/A year-over-year to -$8978.7 in Q1 2022, while the trailing twelve-month figure through Dec 2022 was -$8978.7 (up 97.83% YoY) and the FY2022 annual result came in at -$8162.0, up 96.82% from the prior year.
Equity Income improved to -$8978.7 in Q1 2022 per PRQR's latest filing, from -$97237.5 in the prior quarter.
Over five years, Equity Income peaked at $293269.8 in Q2 2019 and troughed at -$155665.9 in Q3 2021.
A 4-year average of $14857.4 and a median of -$33127.3 in 2020 frame the typical range for Equity Income.
The sharpest annual moves came in 2020 and 2021: Equity Income slumped 214.31% in 2020, then sank 56.84% in 2021.
Over 4 years, Equity Income stood at $54237.5 in 2019, then plunged by 214.31% to -$61999.1 in 2020, then slumped by 56.84% to -$97237.5 in 2021, then soared by 90.77% to -$8978.7 in 2022.
According to Business Quant data, Equity Income over the past three periods registered -$8978.7, -$97237.5, and -$155665.9 for Q1 2022, Q4 2021, and Q3 2021 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	ProQR Therapeutics	206.80 Mn	111.86 Mn	-	-

Download Data